



S10 Fig. History and images of patient DMG23 with *KRAS* mutation. Integrative genomics viewer, magnetic resonance imaging and FDG PET images of patient DMG23 with *KRAS* mutation who received pan-RAF and MEK inhibitors. Interim FDG PET images at 15 days after treatment show the metabolic response with decreased tumor uptake and improved metabolism of the left pons. CCRT, concurrent chemoradiotherapy; FDG, fluorodeoxyglucose; PET, positron emission tomography; SUV, standard uptake value; TMZ, temozolomide.